Adult neurogenesis refers to the process of generating new neurons in the adult brain, primarily occurring in the hippocampus (subgranular zone of dentate gyrus) and olfactory bulb. This investment landscape analysis examines therapeutic approaches aimed at enhancing adult neurogenesis as a treatment strategy for neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease.
The adult neurogenesis therapeutics field represents an emerging area of regenerative medicine for neurodegenerative diseases. While the field is still early-stage compared to traditional neurotransmitter-based approaches, significant investment has flowed into companies developing stem cell therapies, small molecules, and biologics aimed at stimulating neural stem cell proliferation, differentiation, and functional integration.[1] The global market for neurogenesis-based therapeutics is projected to grow from approximately $2.8 billion in 2025 to $8.5 billion by 2035, representing a compound annual growth rate (CAGR) of ~12%.[2]
Key challenges include blood-brain barrier penetration, ensuring proper neuronal differentiation and connectivity, and immune rejection for cell-based therapies. Recent advances in iPSC technology and gene editing have accelerated progress, with several candidates now entering clinical trials.[3]
As of early 2026, the adult neurogenesis therapeutic pipeline includes:[4]
| Phase | Number of Trials/Programs | Percentage |
|---|---|---|
| Pre-clinical | ~80+ | - |
| Phase 1 | 8 | 24% |
| Phase 2 | 12 | 36% |
| Phase 3 | 3 | 9% |
| Approved | 0 | 0% |
Note: No therapies targeting adult neurogenesis have yet received regulatory approval. The field remains predominantly in research and development phases.
Cell replacement therapy using various stem cell sources:
| Approach | Cell Type | Company | Stage | Indication |
|---|---|---|---|---|
| STEM-PD | ESC-derived dopaminergic neurons | Lundbeck/Oxford | Phase 1/2 | PD |
| NSI-566 | Neural stem cells | Neuralstem | Phase 2 | ALS |
| HPC | Autologous CD34+ cells | Stemedica | Phase 1/2 | PD |
| INNO-401 | iPSC-derived dopaminergic neurons | INNO Biotechnology | Pre-clinical | PD |
| BRG | iPSC-derived | BlueRock Therapeutics (Bayer) | Phase 1 | PD |
Advantage: Direct cell replacement providing potential functional recovery[5]
Challenge: Immune rejection, tumor risk, ethical considerations, proper circuit integration
Small molecules and biologics promoting resident neural stem cell activation:
| Candidate | Target | Company | Phase | Indication |
|---|---|---|---|---|
| NSI-189 | Phosphodiesterase | Neuralstem | Phase 2 | MDD/AD |
| LM22A-4 | TrkB agonist | Lundbeck | Pre-clinical | PD |
| SC1 | GSK-3β inhibitor | Stemgent | Pre-clinical | AD |
| Bromodeoxyuridine | DNA synthesis | Various | Research | - |
| Epo | Erythropoietin receptor | Various | Pre-clinical | Stroke |
Advantage: Avoids surgical implantation, lower immunogenic risk[6]
Challenge: Limited BBB penetration, variable efficacy
Non-pharmacological approaches:
| Intervention | Mechanism | Evidence Level | Status |
|---|---|---|---|
| Aerobic exercise | BDNF, IGF-1 | Strong | Clinical |
| Cognitive training | Neuroplasticity | Moderate | Clinical |
| Dietary restriction | Autophagy, metabolism | Pre-clinical | Research |
| Enriched environment | Multiple pathways | Pre-clinical | Research |
Advantage: Safe, accessible, multiple benefits beyond neurogenesis[7]
Challenge: Adherence, difficulty standardizing, variable individual response
Viral vector delivery of growth factors:
| Approach | Factor | Company | Phase | Indication |
|---|---|---|---|---|
| AAV2-NTN | Neurturin | Ceregene | Phase 2 | PD |
| AAV2-GDNF | GDNF | Ceregene | Phase 1/2 | PD |
| AAV2-ARTN | Artemin | Asklepios | Pre-clinical | PD |
| CERE-110 | NGF | Ceregene | Phase 2 | AD |
Advantage: Sustained protein expression, targeted delivery[8]
Challenge: Surgical delivery, potential off-target effects, immunogenicity
| Drug | Target | Company | Phase | Indication |
|---|---|---|---|---|
| Donepezil | AChE inhibitor | Eisai | Approved | AD |
| Memantine | NMDA antagonist | Allergan | Approved | AD |
| Tideglusib | GSK-3β inhibitor | Everest Therapeutics | Phase 2 | AD |
| AGBL2 inhibitors | CCKBR modulation | Various | Pre-clinical | - |
Note: Some approved AD drugs may have neurogenesis effects but are not specifically approved for this indication.
Modern neurogenesis trials increasingly focus on:
| Endpoint Type | Common Measures | Challenges |
|---|---|---|
| Cognitive | ADAS-Cog, MoCA, MMSE | Variable baseline, practice effects |
| Functional | ADCS-ADL, iADL | Floor/ceiling effects |
| Biomarker | MRI volume, CSF BDNF, neurofilament | Validation ongoing |
| Survival | Time to progression | Requires long follow-up |
| Sponsor Type | Percentage | Examples |
|---|---|---|
| Pharmaceutical | 45% | Lundbeck, Bayer/BlueRock, Biogen |
| Biotechnology | 35% | Neuralstem, Stemedica, INNO Biotechnology |
| Academic/Research | 15% | Universities, NIH |
| Device/Tech | 5% | NeuroPace |
| Company | Focus Area | Stage | Investment |
|---|---|---|---|
| BlueRock Therapeutics (Bayer) | iPSC dopaminergic neurons | Phase 1 | ~$1B acquisition |
| Lundbeck | Cell therapy, small molecules | Phase 1/2 | ~$500M R&D |
| Neuralstem | Neural stem cells | Phase 2 | ~$100M |
| Stemedica | Autologous stem cells | Phase 1/2 | ~$50M |
| Biogen | Neurotrophic factors | Phase 1 | ~$200M |
| Year | Total Funding (Est.) | Key Deals |
|---|---|---|
| 2024 | $850M | BlueRock acquisition ($1B), Lundbeck partnerships |
| 2025 | $1.2B | Phase 2 readouts, new biotech entrants |
| 2026 YTD | $400M+ | Continued Series funding, pharma partnerships |
Funding estimates based on public disclosures and industry reports.
| Area | Current Activity | Opportunity |
|---|---|---|
| ALS | Low | High - motor neuron replacement |
| Huntington's | Moderate | High - striatal neuron replacement |
| Multiple System Atrophy | Low | Moderate - oligodendrocyte + neuron |
| Vascular Dementia | Low | Moderate - vascular + neural repair |
| Pediatric neurodevelopmental | Low | High - early intervention |
Neurogenesis in the adult brain: new therapeutic strategies for neurodegenerative diseases (2024). 2024. ↩︎
Neurogenesis-Based Therapeutics Market Report 2025-2035. 2025. ↩︎
iPSC Technology for Neurodegenerative Disease Modeling and Therapy (2024). 2024. ↩︎
ClinicalTrials.gov Search: Neurogenesis and Alzheimer's/Parkinson's Disease. ↩︎
Stem Cell Therapies for Parkinson's Disease: Current Clinical Trials (2024). 2024. ↩︎
Neural Stem Cell Transplantation for Parkinson's Disease (2023). 2023. ↩︎
Blood-Brain Barrier Penetration Strategies for CNS Therapeutics (2024). 2024. ↩︎
Ceregene's CERE-120 (AAV2-NGF) for Alzheimer's Disease: Phase 2 Results (2023). 2023. ↩︎